Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Ryan

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Health Technology Assessment (Winchester, England)|May 15, 2023
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trialUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
Journal of Clinical Epidemiology|November 16, 2010
Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking studyNyaladzi Balogun, Aleksandra Gentry-Maharaj, Eva L Wozniak, et al.
Health Technology Assessment (Winchester, England)|October 16, 2023
Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trialsUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
The Lancet. Oncology|July 14, 2019
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control studyNuno R Nené, Daniel Reisel, Andreas Leimbach, et al.
Genome Medicine|December 23, 2017
The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancerMartin Widschwendter, Michal Zikan, Benjamin Wahl, et al.
Trials|March 2, 2021
UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysisMatthew Burnell, Aleksandra Gentry-Maharaj, Steven J Skates, et al.
Oncotarget|December 2, 2016
Novel risk models for early detection and screening of ovarian cancerMatthew R Russell, Alfonsina D'Amato, Ciaren Graham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2017
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian CancerWei-Lei Yang, Aleksandra Gentry-Maharaj, Archana Simmons, et al.
Ebiomedicine|January 14, 2025
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCSJacob S Bedia, Ian J Jacobs, Andy Ryan, et al.
Gynecologic Oncology|November 19, 2023
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Aleksandra Gentry-Maharaj, Andy Ryan, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Health Technology Assessment (Winchester, England)|May 15, 2023
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trialUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
Journal of Clinical Epidemiology|November 16, 2010
Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking studyNyaladzi Balogun, Aleksandra Gentry-Maharaj, Eva L Wozniak, et al.
Health Technology Assessment (Winchester, England)|October 16, 2023
Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trialsUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
The Lancet. Oncology|July 14, 2019
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control studyNuno R Nené, Daniel Reisel, Andreas Leimbach, et al.
Genome Medicine|December 23, 2017
The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancerMartin Widschwendter, Michal Zikan, Benjamin Wahl, et al.
Trials|March 2, 2021
UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysisMatthew Burnell, Aleksandra Gentry-Maharaj, Steven J Skates, et al.
Oncotarget|December 2, 2016
Novel risk models for early detection and screening of ovarian cancerMatthew R Russell, Alfonsina D'Amato, Ciaren Graham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2017
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian CancerWei-Lei Yang, Aleksandra Gentry-Maharaj, Archana Simmons, et al.
Ebiomedicine|January 14, 2025
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCSJacob S Bedia, Ian J Jacobs, Andy Ryan, et al.
Gynecologic Oncology|November 19, 2023
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)James Dilley, Aleksandra Gentry-Maharaj, Andy Ryan, et al.
Pageof 8